Our breakthrough, proprietary technology platform engineered to enhance drug absorption
End-to-end, in-house control of formulation, development, and manufacturing capabilities
Our proprietary cannabinoid composition for the management of pain and inflammation
Partnering with the world’s leading research institutions and doctors to support FDA-authorized investigator-initiated clinical trials
Learn more about cannabidiol from the medical community and regulators
We are modernizing the way medicines are taken
Experts in drug development and delivery, manufacturing, and commercialization
Recent media coverage regarding Orcosa
Company news and announcements
December 21, 2020 – Orcosa is pleased to report the enrollment of the first patient participating in an investigator-initiated multicenter Phase 1/2 clinical trial utilizing ORAVEXX™ at NYU Langone Health Orthopedic Hospital (“NYU Langone”).
The trial (NCT04672252), an investigator-initiated multicenter, randomized, double-blind, placebo-controlled clinical trial led by Principal Investigator Dr. Michael J. Alaia of NYU Langone and conducted in partnership with Baptist Health/Jacksonville Orthopaedic Institute, aims to evaluate the safety and impact on post-operative pain of cannabidiol (CBD) delivered utilizing Orcosa’s Rapid Infusion Technology (RITe™) Platform. The trial, which plans to enroll 100 patients undergoing arthroscopic rotator cuff repair, will also evaluate patient satisfaction and changes in opioid consumption over a 14-day postoperative period.
RITe™ tablets are fast-acting, easy-to-take tablets engineered to enhance drug absorption. ORAVEXX™ is a non-addictive proprietary cannabidiol composition that utilizes the RITe™ Platform to treat pain quickly and address the historical issues that CBD research has suffered, including inaccurate dosing, poor bioavailability, and difficult administration. ORAVEXX™ and its matching placebo contain no THC and have been made available to independent investigators seeking to conduct well-designed clinical research in accordance with FDA regulations.